Weight Loss Drugs Continue to Power Denmark’s Economy

January 13, 2025

A picture of a slide adjusting scale

(Apricitas Economics) – This Thanksgiving, many Americans ended up with more leftovers than usual—the use of recently discovered GLP-1 drugs is rapidly increasing as millions of people turn to them for help in battling obesity and cardiovascular diseases. These drugs work as appetite suppressants, helping patients regulate food intake by reducing feelings of hunger, and they are one of few medications able to reliably induce long-run weight loss and its downstream health benefits. Thus, prescriptions for Ozempic (a GLP-1 diabetes medication often sought for weight loss despite not being FDA-approved for that purpose) and Wegovy (an explicitly obesity-treating drug) are both on the rise—and that’s been great news for the drugs’ manufacturer, Danish pharmaceutical giant Novo Nordisk. (Read More)